Acorda Therapeutics Company Profile (NASDAQ:ACOR)

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACOR
  • CUSIP: 00484M10
  • Web:
  • Market Cap: $1.27 billion
  • Outstanding Shares: 46,640,000
Average Prices:
  • 50 Day Moving Avg: $24.20
  • 200 Day Moving Avg: $19.91
  • 52 Week Range: $13.60 - $33.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 38.86
  • P/E Growth: 0.51
Sales & Book Value:
  • Annual Revenue: $535.06 million
  • Price / Sales: 2.37
  • Book Value: $14.79 per share
  • Price / Book: 1.84
  • EBITDA: $49.45 million
  • Net Margins: -8.02%
  • Return on Equity: -6.37%
  • Return on Assets: -3.23%
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 2.39%
  • Quick Ratio: 1.98%
  • Average Volume: 802,775 shs.
  • Beta: 1.68
  • Short Ratio: 12.41

Frequently Asked Questions for Acorda Therapeutics (NASDAQ:ACOR)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Thursday, July, 27th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.13 by $0.16. The firm earned $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. Acorda Therapeutics had a negative net margin of 8.02% and a negative return on equity of 6.37%. Acorda Therapeutics's revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?

9 analysts have issued 12-month price targets for Acorda Therapeutics' shares. Their predictions range from $18.00 to $35.00. On average, they anticipate Acorda Therapeutics' share price to reach $23.25 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.

What are analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. According to Zacks Investment Research, "Acorda submitted regulatory applications for its late stage Parkinson’s candidate, Inbrija (formerly known as CVT-301) in the U.S. and plans to file for the same in the EU by 2017-end. However, Inbrija recently received a refusal to file letter from the FDA which is concerning as it would delay its commercial launch. Moreover, the company’s key multiple sclerosis drug Ampyra is facing patent challenges in the United States. Hence, Acorda’s dependence on Ampyra for a major part of its revenue is concerning. The company has its share of pipeline setbacks too with discontinuation of a few late stage programe which is also a matter of concern . On the flip side, Ampyra showed improvement in performance sequentially despite patent challenges. The company is also working on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price has outperformed the industry so far this year." (10/18/2017)
  • 2. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)
  • 3. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen M.D., President,Chief Executive Officer, Director
  • Richard P. Batycky Ph.D., Chief Technology Officer and Site Head
  • David Lawrence, Chief Business Operations, Principal Accounting Officer
  • Andrew R. Blight Ph.D., Chief Scientific Officer
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
  • Burkhard Blank M.D., Chief Medical Officer
  • Andrew Hindman, Chief Business Development Officer
  • Lauren M. Sabella, Chief Commercial Officer
  • Barry E. Greene, Independent Director
  • Peder K. Jensen M.D., Independent Director

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SCOPIA CAPITAL MANAGEMENT LP (18.20%) and SCOPIA CAPITAL MANAGEMENT LP (16.50%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $27.20.

MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $23.25 (14.52% downside)
Consensus Price Target History for Acorda Therapeutics (NASDAQ:ACOR)
Price Target History for Acorda Therapeutics (NASDAQ:ACOR)
Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell -> Sell$20.00N/AView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingHold$18.00LowView Rating Details
8/31/2017Stifel NicolausReiterated RatingBuy$30.00 -> $26.00LowView Rating Details
8/30/2017Janney Montgomery ScottReiterated RatingHold$18.00LowView Rating Details
8/29/2017Cowen and CompanyReiterated RatingBuy$35.00LowView Rating Details
7/10/2017Jefferies Group LLCInitiated CoverageHold -> Hold$22.00MediumView Rating Details
6/6/2017J P Morgan Chase & CoSet Price TargetHold$24.00LowView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
11/23/2016Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Earnings History by Quarter for Acorda Therapeutics (NASDAQ ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.69N/AView Earnings Details
7/27/2017Q2 2017$0.13$0.29$139.81 million$139.40 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.03)$0.26$0.12
Q3 20172$0.21$0.56$0.39
Q4 20172$0.32$0.76$0.54
(Data provided by Zacks Investment Research)


Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acorda Therapeutics (NASDAQ:ACOR)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2017David LawrenceInsiderSell250$25.40$6,350.00View SEC Filing  
8/29/2017Scopia Capital Management LpMajor ShareholderBuy766,201$19.23$14,734,045.23View SEC Filing  
8/1/2017Barry E GreeneDirectorSell10,000$21.57$215,700.00View SEC Filing  
7/31/2017Lorin RandallDirectorSell10,000$21.66$216,600.00View SEC Filing  
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.00View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.90View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.00View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acorda Therapeutics (NASDAQ:ACOR)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline logoAcorda Therapeutics (ACOR) and Vertex Pharmaceuticals (VRTX) Head to Head Analysis - October 20 at 10:30 PM logoPricing Pressure, Competition Remain Headwinds for Pharma Stocks - October 18 at 8:52 PM logoAcorda Therapeutics, Inc. (ACOR) Raised to Hold at Zacks Investment Research - October 18 at 1:50 PM logoAcorda Therapeutics, Inc. (ACOR) to Release Quarterly Earnings on Wednesday - October 18 at 2:58 AM logoAcorda Therapeutics, Inc. (ACOR) Given Consensus Rating of "Hold" by Brokerages - October 12 at 6:56 PM logoLeading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board - GlobeNewswire (press release) - October 10 at 8:55 PM logoAcorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled for October 31, 2017 - October 10 at 3:43 PM logoAcorda Therapeutics Inc (ACOR): How Does It Impact Your Portfolio? - October 9 at 9:34 PM logo$151.15 Million in Sales Expected for Acorda Therapeutics, Inc. (ACOR) This Quarter - October 8 at 5:40 AM logoAcorda Therapeutics' (ACOR) Sell Rating Reiterated at Goldman Sachs Group, Inc. (The) - October 7 at 12:58 AM logoGoldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell - - October 6 at 3:47 PM logoIntra-Cellular Therapies Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares Of Common Stock - October 5 at 8:16 PM logoIntra-Cellular Therapies Announces Commencement Of Enrollment Of A Clinical Trial Evaluating ITI-214 In Patients With Parkinson's Disease - October 4 at 3:12 PM logoAcorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating - October 3 at 3:12 PM logoAcorda Therapeutics, Inc. (ACOR) Earns Hold Rating from Cantor Fitzgerald - September 30 at 7:56 PM logoAcorda: Setback And Opportunity - Seeking Alpha - September 28 at 3:46 PM logoForm 8-K ACORDA THERAPEUTICS INC For: Sep 27 - - September 28 at 1:42 AM logoAcorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by Analysts - September 17 at 4:46 PM logoAcorda to Present at the Cantor Fitzgerald Global Healthcare Conference - Business Wire (press release) - September 13 at 3:44 PM logoAcorda to Present at the Cantor Fitzgerald Global Healthcare Conference - September 13 at 3:43 PM logoShould You Buy Acorda Therapeutics Inc (ACOR) Now? - September 12 at 8:35 PM logoStocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics - September 12 at 2:04 AM logoAcorda Therapeutics Earns RS Rating Upgrade - September 11 at 4:01 PM logoScopia Wants Sale of Acorda Therapeutics - Barron's - September 9 at 1:49 AM logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. - September 8 at 3:47 PM logoStocks Showing Rising Market Leadership: Acorda Therapeutics Earns 83 RS Rating - September 7 at 3:21 PM logoETFs with exposure to Acorda Therapeutics, Inc. : September 7, 2017 - September 7 at 3:21 PM logoFeatured Company News – Acorda Therapeutics Adopts Poison Pill - September 5 at 3:41 PM logoAcorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 - September 5 at 3:41 PM logoAcorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : September 2, 2017 - September 2 at 2:01 AM logoAcorda Therapeutics, Inc. - - September 1 at 3:56 PM logoAcorda Adopts Shareholder Rights Plan - September 1 at 3:55 PM logoBRIEF-Scopia Capital Management ups its stake in Acorda Therapeutics to 18.2 pct from previous stake of 16.5 pct - August 31 at 8:22 PM logoAcorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc.; Encourages Investors to Contact the Firm - August 31 at 8:22 PM logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : August 30, 2017 - August 31 at 8:22 PM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics Inc. (ACOR) - August 31 at 8:22 PM logoJanney Montgomery Scott Reiterates "Hold" Rating for Acorda Therapeutics, Inc. (ACOR) - August 31 at 7:34 PM logoScopia Capital Management Lp Buys 766,201 Shares of Acorda Therapeutics, Inc. (ACOR) Stock - August 31 at 7:20 PM logoBiotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update - August 31 at 3:21 PM logoStifel Nicolaus Reaffirms Buy Rating for Acorda Therapeutics, Inc. (ACOR) - August 31 at 2:32 PM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. - Business Wire (press release) - August 30 at 8:27 PM logoACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm - August 30 at 8:27 PM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. - August 30 at 8:27 PM logoAcorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc ... - PR Newswire (press release) - August 30 at 3:26 PM logoAstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug - August 30 at 3:26 PM logoAcorda Therapeutics, Inc. (ACOR) Receives "Hold" Rating from Cantor Fitzgerald - August 30 at 2:28 PM logoAcorda Therapeutics' (ACOR) Buy Rating Reiterated at Cowen and Company - August 30 at 2:28 PM logoAcorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations - Business Wire (press release) - August 29 at 8:49 PM logoAcorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations - August 29 at 8:49 PM logoACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release) - August 29 at 3:47 PM



Acorda Therapeutics (ACOR) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.